Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Research analysts at Jefferies Group cut their Q3 2016 earnings per share estimates for Sarepta Therapeutics in a research note issued on Monday. Jefferies Group analyst G. Wang now anticipates that the brokerage will earn ($1.38) per share for the quarter, down from their prior estimate of ($1.31). Jefferies Group currently has a “Hold” rating and a $50.00 target price on the stock. Jefferies Group also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($0.51) EPS, FY2016 earnings at ($4.51) EPS, FY2017 earnings at ($2.90) EPS, FY2018 earnings at ($0.15) EPS, FY2019 earnings at $2.49 EPS and FY2020 earnings at $3.89 EPS.

SRPT has been the topic of a number of other reports. Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 target price on the stock in a research note on Thursday, June 2nd. RBC Capital Markets upgraded shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research note on Monday. William Blair reiterated a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. Finally, Needham & Company LLC raised their target price on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, July 22nd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $51.01.

Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.68% during midday trading on Wednesday, reaching $56.11. 5,095,164 shares of the company traded hands. The firm’s 50 day moving average price is $28.17 and its 200 day moving average price is $21.37. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $58.87. The firm’s market capitalization is $2.69 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the business posted ($0.87) EPS.

In related news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.90% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the last quarter. State Street Corp boosted its stake in Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at $13,506,000. 72.09% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.